The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity, efficacy, and safety of nab-paclitaxel (Nab-P) and gemcitabine (G) in heaviliy pretreated advanced pancreatic cancer (APDAC) patients (pts): A multicenter retrospective analysis.
Antonio Febbraro
No relevant relationships to disclose
Alberto Zaniboni
No relevant relationships to disclose
Vittorina Zagonel
No relevant relationships to disclose
Francesco Di Costanzo
No relevant relationships to disclose
Luigi Maiorino
No relevant relationships to disclose
Paola Bertocchi
No relevant relationships to disclose
Francesca Bergamo
No relevant relationships to disclose
Elisa Giommoni
No relevant relationships to disclose
Guido Giordano
No relevant relationships to disclose